secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019629
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q1 2023 total revenues $40.6M (+239% YoY); Tyvaso DPI drives $23M
--------------------------------------------------------------------------

- Total revenues $40.6M vs $12.0M in Q1 2022, a 239% increase.
- Tyvaso DPI contributed $23M in revenue (collaborations/services $11.4M, royalties $11.7M).
- Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M (acquired mid-2022).
- Loss from operations improved 72% to $6M; cash and investments $166.6M at March 31.
- CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial to start H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/0000950170-23-019629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017023019629/mnkd-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer